Amphetamine News and Research

RSS

Biophor receives FDA 510(k) clearance for distribution of seventh oral fluid screening assay

Biophor Diagnostics, Inc. announces that it has received FDA 510(k) clearance for sale and distribution of its seventh oral fluid screening assay based on the RapidFRET IVD Platform technology. This clearance completes the company's flagship panel for drugs of abuse screening in oral fluid.

19 Oct 2015

Glowing protein may replace fiber optic cable as light source in optogenetics research

Optogenetics has taken neuroscience by storm in recent years because the technique allows scientists to study the brain conveniently in animals, activating or inhibiting selected groups of neurons at the flip of a switch. Most often, scientists use a fiber optic cable to deliver light into the brain.

30 Sep 2015

One in every 17 college students smokes marijuana on daily or near-daily basis

Daily marijuana use among the nation's college students is on the rise, surpassing daily cigarette smoking for the first time in 2014.

1 Sep 2015

AMRI’s total revenue increases $89.5 million to 31% in second quarter 2015

AMRI today reported financial and operating results for the second quarter ended June 30, 2015. "We are very pleased to present another strong financial quarter, with all our divisions achieving excellent results," said William S. Marth, AMRI's president and chief executive officer. "Notably, recent acquisitions, combined with the cost reduction initiatives and efficiency efforts we've made to date, are contributing to continued strong contract margin performance.

4 Aug 2015

Ironshore partners with Restore Health to participate in HLD-200 clinical trial to treat ADHD

Ironshore Pharmaceuticals & Development, Inc. has signed an agreement with Restore Health, a company specializing in personalized medicine, to participate in the fulfillment of a double-blind clinical trial, designed to evaluate the safety and efficacy of HLD-200, a new drug in development to treat Attention-deficit/hyperactivity disorder (ADHD).

4 Aug 2015

New study examines how reasons for illicit marijuana use relate to use of other drugs

Marijuana is the most prevalent drug in the U.S. Approximately 70% of the 2.8 million individuals who initiated use of illicit drugs in 2013 reported that marijuana was their first drug.

30 Jun 2015

Amphetamine-based drug Evekeo effective in treating ADHD symptoms in children

The amphetamine-based drug Evekeo, given once or twice daily to children 6-12 years of age, is effective in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and improving performance in a laboratory classroom setting, according to the results of a new study published in the Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

30 Jun 2015

New technology can detect illegal drugs from a single fingerprint

An innovative technology pioneered by Sheffield Hallam University academics can detect the presence of a range of illegal and designer drugs from a single fingerprint, which could be a valuable new tool in bringing drug dealers and other criminals to justice.

From Sheffield Hallam University 29 Jun 2015

FDA accepts Tris Pharma's Dyanavel XR NDA for review

Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application ("NDA") for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension.

21 May 2015

Discovery paves way for developing treatments for people addicted to cocaine, amphetamines

In a major advance in the field of neuropsychiatry, researchers in the Vollum Institute at Oregon Health & Science University have illuminated how cocaine and amphetamines disrupt the normal functioning of the dopamine transporter in the brain.

12 May 2015

AMRI reports financial and operating results for Q4 and FY 2014

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2014.

12 Feb 2015

Altered dopamine signaling may contribute to autism

Newly discovered genetic variations linked to autism spectrum disorder (ASD) disrupt the function of the dopamine transporter, suggesting that altered dopamine signaling contributes to this common developmental condition, according to a Vanderbilt University-led research team.

31 Jan 2015

University of Copenhagen researchers move closer to developing antidote against cocaine addiction

Researchers at the University of Copenhagen have gained new insight into the mechanism behind a protein dopamine transporter that could help in the development of future medical treatment against cocaine addiction.

14 Jan 2015

LCS Therapeutics collaborates to commercialize patent on method to treat binge eating disorder

LCS Therapeutics announced today that it has entered into a strategic collaboration with Lucerne Biosciences, LLC to commercialize U.S. Patent No. 8,318,813 entitled "Method of Treating Binge Eating Disorder."

26 Dec 2014

Health Canada monitors recall of Jetfuel Superburn containing undeclared drug substances

"Jetfuel Superburn" is being recalled after Health Canada tests confirmed it contains two undeclared amphetamine-like drug substances that pose serious health risks (beta-methylphenethylamine and phenylpropylmethylamine).

25 Dec 2014

Psychiatric comorbidities predict bipolar disorder in ADHD children

Children with attention deficit/hyperactivity disorder who also have conduct disorder/oppositional defiant disorder or anxiety disorder are at an increased risk of developing bipolar disorder, research shows.

17 Dec 2014

Study finds link between contraband cigarette and illicit drug use among teens in Canada

A University of Alberta economics professor has discovered a link between contraband cigarette use and illicit drug use among Canadian teens.

17 Dec 2014

HLD-200 successfully meets primary endpoint in Phase III study

Highland Therapeutics Inc., a pharmaceutical company, today announced that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. has reported positive top-line results from its recently completed Phase III study.

11 Nov 2014

Mice may hold clues in development of ADHD, autism and bipolar disorder

A darting mouse may hold an important clue in the development of Attention Deficit Hyperactivity Disorder (ADHD), autism and bipolar disorder, according to a study by a Vanderbilt University-led research team recently published in the Proceedings of the National Academy of Sciences.